Finoriq research workspace
Aurinia Pharmaceuticals Inc. (AUPH) SEC Filings & Filing Highlights
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to. Review AUPH SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
- Company
- Aurinia Pharmaceuticals Inc. (AUPH)
- Ticker
- AUPH
- Market Cap
- $2B
- Latest Price
- $15.36
- Industry
- Biotech & Pharma
Aurinia Pharmaceuticals Inc. (AUPH) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Aurinia Pharmaceuticals Inc. (AUPH).
| Event | Form | Date |
|---|---|---|
| Aurinia Pharmaceuticals Inc. held its annual general meeting of shareholders virtually on June...(a)Aurinia Pharmaceuticals Inc. (the "Corporation") held its annual general meeting of shareholders virtually on June 3, 2026 (the "2026 Me... | 8-K5.07 | 2026-06-04 |
| Aurinia Pharmaceuticals Inc.: Acquisition or asset dispositionAs previously disclosed by Aurinia Pharmaceuticals Inc. (“Ultimate Parent” or “Aurinia”) in its Current Report on Form 8-K filed with the S... | 8-K2.01 | 2026-05-11 |
| Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and...Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress | 8-K2.02 | 2026-05-07 |
| Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Cont...Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right | 8-K7.01 | 2026-04-03 |
| Agreement and Plan of MergerOn March 30, 2026, Aurinia Pharma U.S., Inc., a Delaware corporation (“Parent”), entered into an Agreement and Plan of Merger (the “Merger... | 8-K1.01 | 2026-04-03 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.